IMEXHS Limited - Full Year Results and Q4 Activity Report for FY25
IMEXHS Limited (ASX: IME) has reported full-year results for FY25, achieving revenue of AU$29.0 million, a 10% increase from the previous year and surpassing its guidance. The company also reached an underlying EBITDA of AU$1.6 million, significantly up from AU$0.5 million in FY24. For Q4 FY25, IMEXHS achieved revenue of AU$8.1 million, a 33% year-on-year increase, with recurring revenue of AU$7.6 million, excluding one-offs.
The company’s annualized recurring revenue (ARR) stood at AU$34.8 million as of 31 December 2025, marking a 16% growth compared to the previous year. Notably, Q4 FY25 included significant contract renewals and expansions, such as a Colombian software deal worth AU$348,000 in NARR, enhancing IMEXHS’s revenue base moving into FY26. The company’s cash position strengthened to AU$3.3 million by the end of the quarter. IMEXHS remains focused on expanding its software and radiology services across 18 countries.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
IMEXHS Limited - Full Year Results and Q4 Activity Report for FY25
IMEXHS Limited (ASX: IME) has reported full-year results for FY25, achieving revenue of AU$29.0 million, a 10% increase from the previous year and surpassing its guidance. The company also reached an underlying EBITDA of AU$1.6 million, significantly up from AU$0.5 million in FY24. For Q4 FY25, IMEXHS achieved revenue of AU$8.1 million, a 33% year-on-year increase, with recurring revenue of AU$7.6 million, excluding one-offs.
The company’s annualized recurring revenue (ARR) stood at AU$34.8 million as of 31 December 2025, marking a 16% growth compared to the previous year. Notably, Q4 FY25 included significant contract renewals and expansions, such as a Colombian software deal worth AU$348,000 in NARR, enhancing IMEXHS’s revenue base moving into FY26. The company’s cash position strengthened to AU$3.3 million by the end of the quarter. IMEXHS remains focused on expanding its software and radiology services across 18 countries.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au